ApoC-II Mimetic Peptides for Hypertriglyceridemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypertriglyceridemia, such as fibrates and omega-3 polyunsaturated fatty acids, have not been proven to effectively lower the risks associated with elevated triglycerides, including cardiovascular disease and acute pancreatitis, and there is a need for new therapeutic agents that can address both common and genetically caused forms of the condition.
Innovation Solution
Development of apoC-II mimetic peptides that are multihelical, with amphipathic domains capable of binding to lipids and lipoproteins, and activating lipoprotein lipase, allowing them to lower triglyceride levels both in vitro and in vivo, even in cases of LPL deficiency or elevated apoC-III levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If fibrates and omega-3 polyunsaturated fatty acids are used to treat hypertriglyceridemia, then triglyceride levels are reduced, but the risks of cardiovascular disease and acute pancreatitis are not effectively lowered
Solution Approach 1:
The patent creates a simplified copy of the natural apoC-II peptide (comprising only residues 40-57) that replicates its triglyceride-lowering function. This copy bypasses the limitations of existing treatments by directly activating LPL, thereby reliably reducing both triglyceride levels and associated cardiovascular and pancreatic risks
Solution Approach 2:
The invention changes the molecular parameter from full-length apoC-II (79 residues) to a truncated version (40-57 residues), optimizing the peptide for enhanced LPL activation while maintaining triglyceride-lowering efficacy and improving safety profile by eliminating regions that may cause adverse effects
2Quantity of substance
If conventional treatments are used for hypertriglyceridemia, then some triglyceride reduction is achieved, but they fail to address genetically caused forms of the condition
Solution Approach 1:
The apoC-II(40-57) peptide demonstrates universal efficacy across multiple hypertriglyceridemia etiologies including common forms (obesity, diabetes, alcohol) and genetically caused forms (LPL deficiency, apoC-II deficiency). The peptide works by directly activating LPL, a mechanism that bypasses the need for endogenous apoC-II and functions regardless of the underlying cause
3Quantity of substance
If apoC-III levels are elevated, then triglyceride metabolism is impaired, but existing treatments cannot effectively displace apoC-III from lipoproteins
Solution Approach 1:
The apoC-II(40-57) peptide acts as an intermediary that competes with and displaces apoC-III from lipoprotein surfaces. By binding to lipoproteins and activating LPL, it overrides the inhibitory effect of elevated apoC-III, restoring triglyceride metabolism in conditions where apoC-III levels are pathologically high
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The apoC-II mimetic peptides effectively reduce triglyceride levels, addressing both common and genetically caused hypertriglyceridemia, and can displace apoC-III from lipoproteins, providing a therapeutic option for conditions where LPL is diminished or apoC-III levels are elevated, thereby reducing the risk of cardiovascular disease and pancreatitis.
Implementation Method 1
one or more of the helical domains is amphipathic, conferring on the peptide the ability to bind to lipids and/or to the surface of lipoproteins
Implementation Method 2
another of the helical domains activates LPL
Data Source
AI summary
The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.